Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
01 avr. 2024 08h00 HE
|
Biora Therapeutics, Inc.
Biora has entered into definitive agreements for the purchase and sale of 5,454,548 shares of common stock.
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
26 mars 2024 16h05 HE
|
Biora Therapeutics, Inc.
All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial. Management to host conference call today at 4:30 PM ET.
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
18 mars 2024 08h00 HE
|
Biora Therapeutics, Inc.
Biora's management will host a webcast and conference call on Tuesday, March 26, 2024, after the close of financial markets.
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
11 mars 2024 08h00 HE
|
Biora Therapeutics, Inc.
Monetization of legacy asset brings in $3 million in nondilutive capital; note exchange brings in another $2.8 million in capital, reduces net debt
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
26 févr. 2024 08h00 HE
|
Biora Therapeutics, Inc.
Data from SAD cohort expected to be shared during March corporate update; MAD cohorts to begin dosing in March.
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
08 févr. 2024 08h00 HE
|
Biora Therapeutics, Inc.
Dr. Ariella Kelman to participate in panel titled "The Next Evolutionary Steps in Addressing IBD" on Feb 28, 2024.
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
22 janv. 2024 08h00 HE
|
Biora Therapeutics, Inc.
Biora will participate in a virtual fireside chat hosted by H.C. Wainwright & Co. on Monday, January 29, 2024 at 11:00 AM Eastern / 8:00 AM Pacific.
Biora Therapeutics Provides Outlook for 2024
16 janv. 2024 08h00 HE
|
Biora Therapeutics, Inc.
Biora anticipates 2024 catalysts, including clinical study results for NaviCap™ platform and progress on pharma partnerships for BioJet™ platform.
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
08 janv. 2024 08h00 HE
|
Biora Therapeutics, Inc.
SAD/MAD study to evaluate safety and PK/PD of BT-600 drug-device combination, including concentrations in colon tissue
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
02 janv. 2024 08h00 HE
|
Biora Therapeutics, Inc.
Biora's BioJet™ drug delivery platform exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical study.